ADVANZ's product incorporates a prefilled syringe and a special version of SAN-Light needle that was customized to fit to the drug' parameters and users' needs
DALI Medical Devices, an innovative developer and distributor of drug delivery devices, today announced the first commercial implementation of its SAN-Light passive safety needle.
SAN-Light was chosen to be used with ADVANZ PHARMA’s MYTOLAC®/MYRELEZ® – the first generic lanreotide drug product for the treatment of acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs) – which to date has been launched in two EU markets.
ADVANZ’s product incorporates a prefilled syringe and a special version of SAN-Light needle that was customized to fit to the drug’ parameters and users’ needs. SAN-Light was selected for the product in large part because of its user-friendly design and easy customization to fit the syringe.
SAN-Light is a unique, single-use sterile hypodermic safety needle that is compatible with any Luer-lock syringe for subcutaneous or intramuscular drug administration. It is part of DALI’s SAN® (Safe Auto Needle) family of safety injectable drug delivery devices, all of which enable a more safe and easy-to-use injecting experience for a wide range of formulations.
The SAN-Light enables an enhanced experience for patients and the people who administer the injections, whether they are healthcare professionals, family members, or patients. The automatically activated (passive) needle shield reduces needle-stick injuries, and the partially hidden needle alleviates needle anxiety. Additional design features further facilitate injections.
“We are delighted to have worked with ADVANZ PHARMA on this important, unique solution,” said David Daily, CEO of DALI. “It’s a win-win collaboration that helps patients and enhances the commercialization of ADVANZ PHARMA’s drug product by enabling a better experience and ease of administration.”
Source: Company Press Release